{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-053197","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.055964+00:00","generated_at":"2026-06-02T22:04:29.062394+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Axsome Q1 net product revenue $75M (+160% YoY); net loss $68.4M; pipeline milestones on track","bullets":["Auvelity net sales $53.4M (+240% YoY); Sunosi net revenue $21.6M (+64% YoY).","Net loss $68.4M ($1.44/diluted share) vs $11.2M loss in Q1 2023 which included $62M one-time gain.","Cash $331.4M at March 31, 2024; company expects funds to support operations into cash flow positivity.","NDA resubmission for AXS-07 in migraine and NDA submission for AXS-14 in fibromyalgia targeted for Q2 2024.","Positive Phase 3 SYMPHONY trial of AXS-12 in narcolepsy; Phase 3 ACCORD-2 for AXS-05 in Alzheimer's agitation initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-053197","json":"https://secwatch.observer/filing/0000950170-24-053197.json","markdown":"https://secwatch.observer/filing/0000950170-24-053197.md","text":"https://secwatch.observer/filing/0000950170-24-053197.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024053197/0000950170-24-053197-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024053197/axsm-20240506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:04:29.062394+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6ee411e5a2f1d315b432497964cc3289fb708db4","claim":"Axsome Therapeutics, Inc. reported first quarter of 2024 results: revenue $75.0 million, net income $68.4 million, EPS $(1.44) per share.","evidence_excerpt":"Total net product revenue for the first quarter of 2024 was $75.0 million, representing 160% year-over-year growth.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024053197/0000950170-24-053197-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Revenue","value":"$75.0 million"},{"label":"Net income","value":"$68.4 million"},{"label":"EPS","value":"$(1.44) per share"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}